A vaccine designed to prevent shingles may hold unexpected keys to slowing dementia and biological aging, as mounting evidence challenges its original purpose.
Data from Wales, Australia, Canada, and other regions reveal consistent patterns: vaccinated individuals experience reduced dementia risk compared to unvaccinated peers.
A 2025 Nature study tracked 280,000 older adults over seven years, finding a 20% lower dementia risk in those who received Zostavax. In Australia, a JAMA analysis of 18,000 participants showed a 1.8 percentage point drop in dementia risk (3.7% vs. 5.5%) after vaccine rollout.
Canadian researchers in The Lancet Neurology reported a 2 percentage-point decline in dementia rates following similar vaccination campaigns.
More recent trials highlight the potential of Shingrix, a newer vaccine. A Nature Communications study of 324,000 adults found Shingrix recipients had a 51% lower dementia risk than unvaccinated individuals.
Another Nature Medicine analysis linked Shingrix to a 17% relative increase in dementia-free time compared to Zostavax. These findings align with biological aging research in the Journal of Gerontology, where 3,800 vaccinated adults exhibited reduced inflammation and improved composite aging scores.
Eileen Crimmins said:
"Our study adds to a growing body of work suggesting that vaccines may play a role in healthy aging strategies beyond solely preventing acute illness."
Eric Topol said:
"If a drug were found to cut the risk of dementia by 20 percent, it would be considered a breakthrough."
Researchers emphasize the methodological strength of "natural experiments"—such as geographic vaccine rollout cutoffs—which help mitigate healthy-user bias.
These designs compare vaccinated and unvaccinated populations in real-world settings, reducing confounding factors like lifestyle differences. However, the mechanisms remain speculative. Some theories suggest the vaccine reduces brain inflammation by preventing varicella-zoster virus reactivation, though causality cannot be confirmed.
Gender disparities emerged in the data: women consistently showed greater dementia risk reduction and molecular aging benefits than men. Shingrix may amplify protective effects compared to Zostavax, but further research is needed to confirm this. The study does not provide clinical guidance.
⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.
Source: Arstechnica | Nature | NIH